Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 5;5(10):100707. doi: 10.1016/j.xkme.2023.100707

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Before vs After Biopsy Clinician Ratings of Prognosis Impact.^a,b,c Abbreviations: CKD, chronic kidney disease; AKI, acute kidney injury. ^aBefore biopsy, clinicians were asked to rate the likelihood the biopsy would provide prognostic information. After biopsy, clinicians were asked how the results affected discussions with patients regarding their prognosis; ^bWilcoxon signed-rank tests for prognosis impact: Overall P < 0.001; CKD P < 0.001; AKI P = 0.02; ^cBefore biopsy, the Likert scale is: (1) extremely unlikely, (2) somewhat unlikely, (3) neither likely nor unlikely, (4) somewhat likely, and (5) extremely likely. After biopsy the Likert scale is: (1) very much not affected, (2) somewhat not affected, (3) neither affected nor not affected, (4) somewhat affected, and (5) very much affected.